A Phase 3 interventional study of Murepavadin and One anti-pseudomonal antibiotic in Pneumonia, sponsored by Polyphor Ltd.. Terminated at 7 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-28.
Sponsored by Polyphor Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 344 studies in Pneumonia with a site in United States — 41 open to participants now, 53 under way, 8 of them phase 3. Pneumonia · United States.
Among the 344 studies in Pneumonia with a site in United States, this one is the 240th largest by enrollment of the 263 interventional ones that give a count, is one of 18 that started in 2018, is one of 49 in phase 3, and was the 183rd registered.
1,566 studies on the registry are indexed under Pneumonia; 266 are open to participants now.
Browse Pneumonia studies →41 of the 344 studies in Pneumonia with a site in United States are open now. Recruiting first, the newest first:
Seattle Institute for Biomedical and Clinical Research · Sites in United States
Ages 18+
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
BioNTech SE · Sites in United States
Ages 18–64 · Healthy volunteers
MiNK Therapeutics · Sites in United States, Ukraine
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 158 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 47 (30%) stop at 75 or younger; 41 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
344 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 81 · Phase 3 55 · Phase 4 32
First in 1994; this study’s year is marked. 18 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2 is below the median of 129 across 976 interventional studies indexed under Pneumonia.
Median enrollment 91 across the 263 interventional studies, 325 across the 78 observational. Of the 257 that completed or were terminated, 101 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
118 of 344 have an industry lead sponsor. The 10 most frequent:
Polyphor Ltd. is the lead sponsor of 11 studies on the registry; none are open to participants now.
Polyphor Ltd. has 2 studies filed under Pneumonia — fewer than ten, so there is no comparison to draw.
22 of the studies in Pneumonia with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07365826Phase 3Vaxcyte, Inc.A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age | 2027-03 |
| NCT07425392Phase 3Vaxcyte, Inc.Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination | 2027-03 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
Add all 22 to your calendar (.ics) → With an account.
Among the 344 studies in Pneumonia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 3, multicenter, open-label, sponsor blinded, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability of intravenous murepavadin given with ertapenem versus an anti-pseudomonal β-lactam based antibiotic in the treatment of nosocomial pneumonia in adult subjects
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Murepavadin + ertapenem
Drug: Murepavadin
One anti-pseudomonal-β-lactam-based antibiotic (either meropenem or piperacillin-tazobactam)
Drug: One anti-pseudomonal antibiotic
Murepavadin + ertapenem
Either meropenem or piperacillin-tazobactam
All cause mortality rates
Time frame: 28 days after start of study treatment
Ran from Oct 2018 to primary completion in Jul 2019, 8 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Murepavadin
Polyphor Ltd.